News & Media

    01/08/2018
    36th Annual J.P. Morgan Healthcare Conference 
    10/17/2017
    Charleston Laboratories, Inc. Resubmits NDA for CL-108 
    08/31/2017
    Charleston Laboratories, Inc. Reacquires Rights to Novel Investigational Treatment CL-108, for Acute Pain and Opioid-Induced Nausea and Vomiting 
    08/25/2017
    Patients Treating Flares of Osteoarthritis with CL-108 Experienced Improvements in Activities of Daily Living Under Actual Conditions of Use 

    Abstract not published in abstract book

    08/25/2017
    What is the likelihood of opioid-induced nausea and vomiting (OINV) in patients who by history are assumed to be not at risk of developing OINV? 

    Abstract not published in abstract book

    03/27/2017
    Prophylactic Antiemetic Use Reduces Opioid Induced Nausea and Vomiting and Improves Patient Recovery in the Outpatient Setting 

    Oak Y, Gregorian R, Kwong W, Kane A, Zou P, Marrett E. J Manag Care Pharm. 2017:23:S91.

    02/15/2017
    Charleston Laboratories, Inc. Announces Senior Global Regulatory Hire 
    02/03/2017
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use 
    01/26/2017
    Charleston Laboratories, Inc. Announces Formation of U.S. Commercial Subsidiary 
    01/24/2017
    Charleston Laboratories, Inc. Expands Senior Management Team with Two Key Appointments in Core Business Areas of Medical & Commercialization 
    10/04/2016
    Health Care Utilization and Costs Associated with Nausea and Vomiting in Patients Receiving Oral Immediate-Release Opioids for Outpatient Acute Pain Management 

    Marrett E, Kwong WJ, Frech F, Qian C. Pain Ther. 2016;5:215-226.

    09/30/2016
    Clinically Meaningful Pain Relief in Patients with Moderate to Severe Acute Pain Treated with CL-108 

    Published abstract book not available

    09/30/2016
    The incidence of opioid-induced nausea and vomiting (OINV) in patients who by history are assumed to be not at risk of developing OINV 

    Published abstract book not available

    09/29/2016
    Patients Treating Flares of Osteoarthritis with CL-108 Experienced Improvements in Activities of Daily Living Under Actual Conditions of Use 

    Published abstract book not available

    09/29/2016
    Results from Using the Nausea Intensity Scale: The Severity Of Nausea is Significantly Reduced by CL-108 Compared with a Standard Hydrocodone/ Acetaminophen Analgesic When Used to Treat Moderate-To-Severe Pain 

    Published abstract book not available

    08/18/2016
    No evidence of increased abuse potential of CL-108, a bi-layered tablet containing hydrocodone/acetaminophen/promethazine, in recreational opioid users 

    Shram M, Levy-Cooperman N, Webster L. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 84

    08/18/2016
    Actual-Use Study of CL-108 for the treatment of flares of osteoarthritis of the knee or hip 

    Aazami H, Glover RM, Kivitz AJ, Oliver D, Ricci DR, Surowitz R, Schachtel B. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 79.

    08/18/2016
    The Efficacy of CL-108 in Preventing Opioid-Induced Nausea and Vomiting (OINV) 

    Daniels SE, Richardson SF, Patrick K, Royall SP, Schachtel E, Lorton MB, Zhang B, Cho S, Schachtel BP. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 79.

    08/18/2016
    The Impact of Nausea on Pain and its Relief 

    Bender R, Schachtel B, Revicki D, Rentz A, Kwong J, Marrett E. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 9.

    08/18/2016
    Use of the Qualities of Pain Index (QPI) to demonstrate beneficial effects on affective and sensory qualities of pain 

    Schachtel B, Hersh E, Zuniga J, Daniels S, Muse D, Patrick K, Oreadi D, Bennett J, Schachtel E, Papas A. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 104.

    08/18/2016
    Patients Treated with CL-108 Over a 5-day Post-Operative Period Use Less Antiemetic Medication for Opioid-Induced Nausea and Vomiting (OINV) than Patients Treated with Standard Hydrocodone/Acetaminophen 

    Hersh EV, Schachtel B. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 41.

    08/18/2016
    Objective evidence of the efficacy of CL-108 compared to standard hydrocodone 7.5 mg/ acetaminophen 325 mg in preventing Opioid-Induced Nausea and Vomiting (OINV) 

    Hersh EV, Schachtel B, Kozarek WJ, Schachtel E. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 80.

    07/31/2016
    Safety and Effectiveness of CL-108 for the Treatment of Moderate-to-Severe Pain Associated with Flares of Osteoarthritis of the Knee or Hip 

    Schachtel B, Marino M, Lazar J, Aazami H, Burnette M, Kivitiz A, Lewis K, Lorton MB, McIlwain H, Munir M, Oliver D, Poland S, Ricci D, Schachtel E, Tseytlin L. Pain Med. 2016;17(2):429.

    07/31/2016
    CL-108 Reduces the Use of Rescue Antiemetic Medications for Opioid-Induced Nausea and Vomiting 

    Hersh E, Marino M, Schachtel B. Pain Med. 2016;17(2):423.

    06/13/2016
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce FDA Acceptance of New Drug Application (NDA) for CL-108 
    06/01/2016
    No evidence of increased abuse potential of CL-108 a bilayered tablet containing hydrocodone/ acetaminophen/promethazine, in recreational opioid users 

    Levy-Cooperman N, Shram M, Webster LR.

    05/11/2016
    Charleston Laboratories, Inc. Announces Presentations at the Annual Scientific Meeting of the American Pain Society 
    04/19/2016
    Healthcare Costs Associated with Nausea and Vomiting in Patients Receiving Oral Immediate-Release Opioids for the Management of Acute Pain in the Outpatient Setting 

    Marrett E, Frech F, Zhang Q, Qian C. JMCP. 2016;22:S114.

    04/01/2016
    Opioid-Induced Nausea and Vomiting (OINV) in Post-Operative Patients: A Comparison of CL-108 to Hydrocodone 7.5 mg/Acetaminophen 325 mg 

    Richardson SF, Patrick K, Daniels SE, Royall SP, Schachtel E, Zhang B, Marino M, Schachtel B. J Pain. 2016;17(4):S83.

    04/01/2016
    Efficacy of CL-108 compared to hydrocodone 7.5 mg/acetaminophen 325 mg in preventing vomiting and the use of anti-emetics, Opioid-Induced Nausea and Vomiting (OINV) 

    Hersh E, Schachtel B, Kozarek W, E Schachtel, Marino M. J Pain. 2016;17(4):S82

    01/20/2016
    Governor Scott Announces Charleston Laboratories, Inc. Expansion Will Create 25 New Jobs 
    01/20/2016
    The Business Development Board of Palm Beach Plays Key Role in Charleston Laboratories, Inc. Expansion 
    10/29/2015
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints 
    09/04/2015
    What is the incidence of opioid-induced nausea and vomiting in patients who do not have immediate post-operative nausea or vomiting? 

    Schachtel B, Marino M, Kozarek W, Schachtel E, Hersh E. (2015) PAINWeek Abstract Book 2015, Postgraduate Medicine, 127:sup1, S83.

    08/20/2015
    Raymond A. Dionne D.D.S., Ph.D Joins Charleston Laboratories, Inc Scientific Advisory Board 
    08/20/2015
    Charleston Laboratories, Inc. Announces Completion of a Second Phase 3 Clinical Trial on its Lead Product, CL-108, and the Appointment of Dr. Raymond Dionne to its Scientific Advisory Board 
    08/03/2015
    Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston’s Second Product, CL-H1T 
    05/13/2015
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Three Poster Presentations at American Pain Society Annual Meeting 
    04/06/2015
    Charleston Laboratories, Inc. Completes Patient Enrollment in a Phase 3 
    04/01/2015
    NEED WORD DOC: The incidence of opioid-induced nausea and vomiting (OINV) in patients with a history that is only suggestive of developing OINV 
    04/01/2015
    Opioid-Induced Nausea and Vomiting (OINV) in patients without immediate post-op nausea/vomiting 

    Hersh E, Kozarek W, Marino M, Schachtel B. Opioid-Induced Nausea and Vomiting (OINV) in patients without immediate post-op nausea/vomiting. J Pain. 2015;16(4):S80.

    04/01/2015
    Affective and sensory qualities of pain complement evaluative measures of opioid analgesia: results from the Qualities of Dental Pain Index (QDPI) 

    Schachtel B, Hersh E, Papas A, Daniels S, Muse D, Patrick K, Bennett J, Schachtel E, Marino M, Zuniga J. J Pain. 2015;16(4):S7.

    04/01/2015
    What is the likelihood of opioid-induced nausea and vomiting (OINV) in patients with a history that is only suggestive of OINV? 

    Hersh E, Papas A, Zuniga J, Daniels S, Muse D, Patrick K, Bennett J, Schachtel E, Marino M, Schachtel B. J Pain. 2015;16(4):S16.

    03/12/2015
    Charleston Laboratories, Inc. & Daiichi Sankyo, Inc. Announce Completion of a Pharmacokinetics Study on CL-108 
    11/20/2014
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Initiate Two Phase 3 Clinical Trials on Charleston’s Lead Product, CL-108 
    10/09/2014
    Prescription for Success 
    09/09/2014
    Charleston Laboratories, Inc. Announces Key Clinical Updates for Novel Drugs 
    09/02/2014
    Safety and efficacy of CL-108 for moderate-to-severe acute pain with reduction of opioid-induced nausea and vomiting 

    Hersh E, Schachtel B, Daniels S, Muse D, Patrick K, Zuniga J, Bennett J, Schachtel E, Papas A. Poster presented at: Pain Week 2014; September 2-6, 2014; Las Vegas, NV.

    08/07/2014
    Charleston Laboratories and Daiichi Sankyo Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US 
    05/08/2014
    Gary A. Peltz, M.D. Joins Charleston Laboratories, Inc Scientific Advisory Board 
    05/08/2014
    Charleston Laboratories, Inc., Bolsters Senior Management Team 
    05/02/2014
    Charleston Laboratories, Inc. Announces Publication of Abstract for CL-108 Phase 3 Study at APS 2014 
    04/30/2014
    Demonstration of the safety and efficacy of CL-108 for moderate-to-severe pain with reduction of opioid-induced nausea and vomiting 

    Schachtel B, Younes N, Zhou J, Schachtel E, Hersh E. Demonstration of the safety and efficacy of CL-108 for moderate-to-severe pain with reduction of opioid-induced nausea and vomiting. J Pain 2014;15(4): S81.

    10/29/2013
    Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain 
    10/09/2013
    Charleston Laboratories, Inc. Announces Research Collaboration with Stanford University 
    07/23/2013
    Charleston Laboratories, Inc Successfully Completes Pre-IND Meeting on New Migraine Treatment 
    04/16/2013
    FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment 
    03/22/2013
    Charleston Laboratories, Inc submitted a request with the U.S. Food and Drug Administration (FDA) for a Pre-Investigational New Drug (Pre-IND) meeting regarding the development of CL-H1T. 
    01/28/2013
    Robert H. Dworkin, Ph.D Joins Charleston Laboratories, Inc Scientific Advisory Board 
    01/28/2013
    Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial 
    01/07/2013
    31st Annual J.P. Morgan Healthcare Conference 
    12/01/2012
    Charleston Laboratories, Inc. Appoints Ryan Baker Executive Vice President and Chief Operating Officer 
    09/03/2012
    Charleston Laboratories, Inc. Appoints Bill Kozarek Ph.D Vice President of Product Development 
    01/09/2012
    30th Annual J.P. Morgan Healthcare Conference 
    11/02/2010
    Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project Grant 
    05/18/2009
    BIO International Convention 2009 
    05/18/2009
    Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108 
    02/12/2009
    Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire 
    02/02/2009
    Charleston Completes Preliminary Research on Nausea-Prone Questionnaire (NPQ) 
    02/02/2009
    Charleston Completes Preliminary Research on Nausea-Prone Questionnaire (NPQ) 
    01/12/2009
    Charleston Labs begins Bioequivalence Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CL-108 
    01/12/2009
    27th Annual J.P. Morgan Healthcare Conference 
    01/12/2009
    Charleston Labs begins Bioequivalence Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CL-108 
    01/09/2009
    Charleston Sucessfully Completes Series A Private Placement 
    10/03/2008
    Charleston Laboratories, Inc. Investigational New Drug CL-108 “Safe to Proceed Testing in Man.” 
    01/07/2008
    26th Annual J.P. Morgan Healthcare Conference 
    11/08/2007
    Charleston completes successful Type B, Pre-IND meeting with FDA’s Division of Anesthesia, Analgesia and Rheumatology Products on November 8, 2007, held at FDA’s Silver Spring, Maryland offices. 
    08/01/2007
    Charleston Laboratories, Inc. Appoints Bernard Schachtel, M.D. Chief Medical Officer 
    08/01/2007
    Charleston Laboratories, Inc. Appoints John F. Ameling V.P of Regulatory Affairs